{"success":true,"data":{"pressRelease":{"id":"17195","rtpr_id":"nACS6lvN2a","ticker":"REPL","exchange":"NASDAQ","all_tickers":["REPL"],"title":"INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL","author":"ACCESSWIRE","published_at":"2026-05-01T14:00:01.053Z","article_body":"NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) / May 1,\n2026 / Pomerantz LLP is investigating claims on behalf of investors of\nReplimune Group, Inc. (\"Replimune\" or the \"Company\") (NASDAQ:REPL). Such\ninvestors are advised to contact Danielle Peyton at newaction@pomlaw.com or\n646-581-9980, ext. 7980.\n\nThe investigation concerns whether Replimune and certain of its officers\nand/or directors have engaged in securities fraud or other unlawful business\npractices.\n\n[Click here for information about joining the class action]\n(https://pr.report/l64h)\n\nOn April 10, 2026, the U.S. Food and Drug Administration published a complete\nresponse letter to Replimune concerning its Biologics License Application for\nRP1 in combination with nivolumab for the treatment of advanced melanoma,\nhaving \"unanimously determined data presented are insufficient to conclude\nsubstantial evidence of effectiveness\".\n\nOn this news, Replimmune's stock price fell $3.06, or 64.28%, to close at\n$1.70 per share on April 13, 2026.\n\nPomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris,\nand Tel Aviv, is acknowledged as one of the premier firms in the areas of\ncorporate, securities, and antitrust class litigation. Founded by the late\nAbraham L. Pomerantz, known as the dean of the class action bar, Pomerantz\npioneered the field of securities class actions. Today, more than 85 years\nlater, Pomerantz continues in the tradition he established, fighting for the\nrights of the victims of securities fraud, breaches of fiduciary duty, and\ncorporate misconduct. The Firm has recovered numerous multimillion-dollar\ndamages awards on behalf of class members. See www.pomlaw.com.\n\nAttorney advertising. Prior results do not guarantee similar outcomes.\n\nSOURCE: Pomerantz LLP\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/business-and-professional-services/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-1162695)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nACS6lvN2a","title":"INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL","author":"ACCESSWIRE","ticker":"REPL","created":"2026-05-01T14:00:01.053Z","tickers":["REPL"],"exchange":"NASDAQ","article_body":"NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) / May 1,\n2026 / Pomerantz LLP is investigating claims on behalf of investors of\nReplimune Group, Inc. (\"Replimune\" or the \"Company\") (NASDAQ:REPL). Such\ninvestors are advised to contact Danielle Peyton at newaction@pomlaw.com or\n646-581-9980, ext. 7980.\n\nThe investigation concerns whether Replimune and certain of its officers\nand/or directors have engaged in securities fraud or other unlawful business\npractices.\n\n[Click here for information about joining the class action]\n(https://pr.report/l64h)\n\nOn April 10, 2026, the U.S. Food and Drug Administration published a complete\nresponse letter to Replimune concerning its Biologics License Application for\nRP1 in combination with nivolumab for the treatment of advanced melanoma,\nhaving \"unanimously determined data presented are insufficient to conclude\nsubstantial evidence of effectiveness\".\n\nOn this news, Replimmune's stock price fell $3.06, or 64.28%, to close at\n$1.70 per share on April 13, 2026.\n\nPomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris,\nand Tel Aviv, is acknowledged as one of the premier firms in the areas of\ncorporate, securities, and antitrust class litigation. Founded by the late\nAbraham L. Pomerantz, known as the dean of the class action bar, Pomerantz\npioneered the field of securities class actions. Today, more than 85 years\nlater, Pomerantz continues in the tradition he established, fighting for the\nrights of the victims of securities fraud, breaches of fiduciary duty, and\ncorporate misconduct. The Firm has recovered numerous multimillion-dollar\ndamages awards on behalf of class members. See www.pomlaw.com.\n\nAttorney advertising. Prior results do not guarantee similar outcomes.\n\nSOURCE: Pomerantz LLP\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/business-and-professional-services/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-1162695)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved."},"type":"article","timestamp":"2026-05-01T14:00:01.086885946Z","server_sent_at_ms":1777644001086},"received_at":"2026-05-01T14:00:01.290Z","source_url":"https://www.accessnewswire.com/newsroom/en/business-and-professional-services/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-1162695"},"analysis":null,"durationMs":null,"modelName":null}}